( NYSE:ABBV )

News from AbbVie A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

21 Apr, 2017, 08:00 ET AbbVie to Present at the Deutsche Bank 42nd Annual Health Care Conference

AbbVie (NYSE: ABBV) will participate in the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3, 2017. William Chase, executive...


21 Apr, 2017, 01:00 ET Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced high SVR12 rates were achieved with 8 weeks of treatment with its...


20 Apr, 2017, 07:30 ET AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 99 percent (n=145/146) of chronic hepatitis C virus (HCV) infected...


19 Apr, 2017, 17:50 ET AbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for the Treatment of Patients with Advanced or Metastatic Squamous Non-Small Cell Lung Cancer and Early-Stage Triple-Negative Breast Cancer

AbbVie, a global biopharmaceutical company, today announced that two Phase 3 studies evaluating veliparib, an investigational, oral poly (adenosine...


07 Apr, 2017, 08:00 ET AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids

AbbVie (NYSE: ABBV), a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced detailed...


06 Apr, 2017, 08:00 ET AbbVie to Host First-Quarter Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its first-quarter 2017 financial results on Thursday, April 27, 2017, before the market opens. AbbVie will host...


05 Apr, 2017, 11:00 ET AbbVie Celebrates 25th Year of its CF Scholarship and is Now Accepting Applications from Students with Cystic Fibrosis

AbbVie, a global biopharmaceutical company, today announced that the 2017 AbbVie CF Scholarship program is now accepting applications for the...


04 Apr, 2017, 07:00 ET AbbVie Announces Ibrutinib (IMBRUVICA®) Supplemental New Drug Application for Previously Treated Chronic Graft-Versus-Host-Disease (cGVHD) Accepted for Review by U.S. FDA

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced a supplemental New Drug Application (sNDA) was accepted for review by the...


30 Mar, 2017, 07:00 ET U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA® (adalimumab) Prescribing Information

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the inclusion of...


28 Mar, 2017, 08:00 ET AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program

AbbVie, a global biopharmaceutical company, and M2Gen, a leading health informatics solutions company, announced today that AbbVie has joined the...


23 Mar, 2017, 07:45 ET Julianne Hough Empowers Women to "Get in the Know" About Endometriosis

AbbVie, a global biopharmaceutical company, today announced that actress, dancer and Emmy Award-winning choreographer Julianne Hough is helping to...


14 Mar, 2017, 08:00 ET AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that priority review has been granted by the Japanese Ministry of Health,...


01 Mar, 2017, 08:00 ET AbbVie to Present at the Barclays Global Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2017. William Chase, executive vice...


27 Feb, 2017, 04:00 ET AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C

AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of...


17 Feb, 2017, 08:00 ET AbbVie Announces $5 Billion Increase to Stock Repurchase Program

The board of directors of AbbVie Inc. (NYSE: ABBV) has authorized a $5 billion increase to AbbVie's existing stock repurchase program. Purchases...


15 Feb, 2017, 08:01 ET AbbVie to Present at the Cowen and Company 37th Annual Health Care Conference

AbbVie (NYSE: ABBV) will participate in the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017. William Chase,...


02 Feb, 2017, 08:00 ET U.S. FDA Grants Priority Review to AbbVie for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug...


27 Jan, 2017, 07:48 ET AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results

AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2016. "The fourth quarter was a...


25 Jan, 2017, 08:00 ET AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy

AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the start of two Phase 2 clinical trial programs to evaluate ABBV-8E12, an...


24 Jan, 2017, 04:00 ET European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie's Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that its marketing authorization application (MAA) has been validated and...


19 Jan, 2017, 07:00 ET U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) approved IMBRUVICA®...


10 Jan, 2017, 09:00 ET AbbVie to Host Fourth-Quarter 2016 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its Fourth-Quarter 2016 financial results on Friday, January 27, 2017. AbbVie will host a live webcast of the...


09 Jan, 2017, 08:00 ET AbbVie Announces Four New Global Research Collaborations Focused on Advancing Next-Generation Science

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced four new collaborations and investments with leading healthcare innovators...


09 Jan, 2017, 07:00 ET Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR[12] Rates in Genotype 1 Japanese Patients

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced high SVR12 rates with 8 weeks of treatment with its investigational,...


22 Dec, 2016, 08:00 ET AbbVie to Present at the 35th Annual J.P. Morgan Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 11, 2017. Richard A. Gonzalez,...